// App-Quantinova.ai

: Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism

Researchers

Presenter

  • Alex C. Spyropoulos

Principal Investigators

  • Veronica Ashton

  • Yen-Wen Chen

  • Bingcao Wu

  • Eric D. Peterson

Medical Centers

  • Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health System, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY

  • Janssen Scientific Affairs, LLC, Titusville, NJ

  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, United States

Locations

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Venous thrombosis

  • Obesity

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Warfarin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved